Exscientia (EXAI) News Today $4.84 +0.15 (+3.20%) (As of 11/20/2024) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period NVIDIA Invested in These 2 AI Stocks, Should You? (EXAI)Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.December 2 at 8:37 AM | marketbeat.comExscientia and Recursion Merge to Revolutionize Drug DiscoveryNovember 21, 2024 | markets.businessinsider.comRecursion, Exscientia officially combine to advance drug discoveryNovember 21, 2024 | markets.businessinsider.comRecursion: No News Isn't Good News When It Comes To Vanilla PipelineNovember 20, 2024 | seekingalpha.comBarclays Sticks to Its Hold Rating for Exscientia Plc (EXAI)November 15, 2024 | markets.businessinsider.comExscientia (NASDAQ:EXAI) Shares Down 5.3% - Time to Sell?Exscientia (NASDAQ:EXAI) Shares Down 5.3% - Here's What HappenedNovember 15, 2024 | marketbeat.comRecursion and Exscientia Merger Approved by ShareholdersNovember 14, 2024 | markets.businessinsider.comRecursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed CombinationNovember 13, 2024 | finanznachrichten.deRecursion, Exscientia shareholders approve proposed combinationNovember 13, 2024 | markets.businessinsider.comBaillie Gifford & Co. Has $18.78 Million Stake in Exscientia plc (NASDAQ:EXAI)Baillie Gifford & Co. cut its position in shares of Exscientia plc (NASDAQ:EXAI - Free Report) by 12.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,848,276 shares of the company's stock after sellingNovember 13, 2024 | marketbeat.comExscientia (NASDAQ:EXAI) Sees Large Volume Increase - Here's WhyExscientia (NASDAQ:EXAI) Sees Strong Trading Volume - Here's WhyNovember 11, 2024 | marketbeat.comExscientia Plc Enhances Board Collaboration with RecursionNovember 6, 2024 | markets.businessinsider.comExscientia (NASDAQ:EXAI) Shares Gap Down - Here's WhyExscientia (NASDAQ:EXAI) Shares Gap Down - Should You Sell?October 21, 2024 | marketbeat.comExscientia plc (NASDAQ:EXAI) Sees Large Decrease in Short InterestExscientia plc (NASDAQ:EXAI - Get Free Report) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totalling 2,890,000 shares, a decline of 9.7% from the September 15th total of 3,200,000 shares. Based on an average daily volume of 676,600 shares, the short-interest ratio is presently 4.3 days. Currently, 2.7% of the shares of the stock are sold short.October 17, 2024 | marketbeat.comVet tranquillizer increases overdose deaths in Yukon, health minister saysOctober 12, 2024 | msn.comBoeing Sacks 17,000 Workers Amid Strike and Safety ConcernsOctober 12, 2024 | nz.finance.yahoo.comRecursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug DiscoveryOctober 12, 2024 | msn.comCapricor reports positive long-term data for DMD drug deramiocelOctober 11, 2024 | msn.comExscientia Set for Strategic Acquisition by RecursionOctober 11, 2024 | finance.yahoo.comRecursion, Exscientia seek support for merger ahead of special meetingOctober 10, 2024 | seekingalpha.comExscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024October 9, 2024 | businesswire.comExscientia (NASDAQ:EXAI) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.com13,086,600 Shares in Exscientia plc (NASDAQ:EXAI) Bought by Novo Holdings A SNovo Holdings A S bought a new stake in Exscientia plc (NASDAQ:EXAI - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,086,600 shares of the company's stock, valued at approximately $66,742,000. ExSeptember 30, 2024 | marketbeat.comAI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech BoomSeptember 24, 2024 | theglobeandmail.comMorgan Stanley Sticks to Its Hold Rating for Exscientia Plc (EXAI)September 24, 2024 | markets.businessinsider.comExscientia (NASDAQ:EXAI) Trading Up 3.8%Exscientia (NASDAQ:EXAI) Shares Up 3.8%September 18, 2024 | marketbeat.comExscientia plc (NASDAQ:EXAI) Shares Bought by Bank of New York Mellon CorpBank of New York Mellon Corp grew its stake in Exscientia plc (NASDAQ:EXAI - Free Report) by 108.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 388,459 shares of the company's stock after pSeptember 18, 2024 | marketbeat.comRecursion: AI Is Only As Good As The DataSeptember 11, 2024 | seekingalpha.comExscientia (NASDAQ:EXAI) Stock Price Down 3.5%Exscientia (NASDAQ:EXAI) Stock Price Down 3.5%September 9, 2024 | marketbeat.comExscientia (NASDAQ:EXAI) Shares Up 4.5%Exscientia (NASDAQ:EXAI) Stock Price Up 4.5%September 4, 2024 | marketbeat.comExscientia (NASDAQ:EXAI) Sees Unusually-High Trading VolumeExscientia (NASDAQ:EXAI) Sees Strong Trading VolumeSeptember 3, 2024 | marketbeat.comShort Interest in Exscientia plc (NASDAQ:EXAI) Grows By 15.7%Exscientia plc (NASDAQ:EXAI - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 3,690,000 shares, a growth of 15.7% from the July 31st total of 3,190,000 shares. Approximately 3.5% of the shares of the stock are short sold. Based on an average trading volume of 593,200 shares, the short-interest ratio is currently 6.2 days.September 2, 2024 | marketbeat.comExscientia Plc (EXAI): A Penny Stock That Will Make You a MillionaireAugust 31, 2024 | msn.comExscientia (NASDAQ:EXAI) Shares Gap Up to $5.66Exscientia (NASDAQ:EXAI) Shares Gap Up to $5.66August 30, 2024 | marketbeat.comExscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 29, 2024 | finance.yahoo.comExscientia (NASDAQ:EXAI) Stock Price Down 4.2%Exscientia (NASDAQ:EXAI) Stock Price Down 4.2%August 27, 2024 | marketbeat.comExscientia plc (NASDAQ:EXAI) Stake Cut by Baillie Gifford & Co.Baillie Gifford & Co. decreased its holdings in shares of Exscientia plc (NASDAQ:EXAI - Free Report) by 3.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,397,618 shares of the company's stock after selAugust 25, 2024 | marketbeat.comExscientia plc (NASDAQ:EXAI) Short Interest Down 12.4% in JulyExscientia plc (NASDAQ:EXAI - Get Free Report) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totalling 3,190,000 shares, a drop of 12.4% from the July 15th total of 3,640,000 shares. Based on an average daily volume of 557,400 shares, the short-interest ratio is presently 5.7 days. Currently, 2.7% of the company's shares are sold short.August 20, 2024 | marketbeat.comExscientia (NASDAQ:EXAI) Stock Price Down 2.8%Exscientia (NASDAQ:EXAI) Stock Price Down 2.8%August 19, 2024 | marketbeat.comExscientia (NASDAQ:EXAI) Issues Quarterly Earnings ResultsExscientia (NASDAQ:EXAI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.05). Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. The business had revenue of $5.60 million during the quarter.August 18, 2024 | marketbeat.comNews Flash: 4 Analysts Think Exscientia plc (NASDAQ:EXAI) Earnings Are Under ThreatAugust 16, 2024 | finance.yahoo.comMaintaining Hold Rating on Exscientia Plc Amid Anticipated Developments and Clinical MilestonesAugust 16, 2024 | markets.businessinsider.comHow A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market UpdatesAugust 15, 2024 | theglobeandmail.comExscientia Business Update for Second Quarter and First Half 2024August 15, 2024 | finance.yahoo.comBarclays Downgrades Exscientia plc - Depositary Receipt () (EXAI)August 14, 2024 | msn.comExscientia (NASDAQ:EXAI) Receives Equal Weight Rating from BarclaysBarclays reaffirmed an "equal weight" rating and set a $5.00 price objective on shares of Exscientia in a research note on Tuesday.August 13, 2024 | marketbeat.comExscientia (NASDAQ:EXAI) Stock Price Down 3.1%Exscientia (NASDAQ:EXAI) Trading Down 3.1%August 13, 2024 | marketbeat.comExscientia (NASDAQ:EXAI) Shares Gap Down to $5.05Exscientia (NASDAQ:EXAI) Shares Gap Down to $5.05August 12, 2024 | marketbeat.comTD Cowen Downgrades Exscientia plc - Depositary Receipt () (EXAI)August 9, 2024 | msn.comExscientia (NASDAQ:EXAI) Stock Rating Reaffirmed by TD CowenTD Cowen reaffirmed a "hold" rating on shares of Exscientia in a research note on Friday.August 9, 2024 | marketbeat.com Get Exscientia News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Is Mocking Elon, But Wait Until They See This Demo (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. EXAI Media Mentions By Week EXAI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXAI News Sentiment▼1.410.87▲Average Medical News Sentiment EXAI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXAI Articles This Week▼25▲EXAI Articles Average Week Get Exscientia News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Wave Life Sciences News Today CG Oncology News Today IDEAYA Biosciences News Today Longboard Pharmaceuticals News Today Keros Therapeutics News Today Centessa Pharmaceuticals News Today Akero Therapeutics News Today Mirum Pharmaceuticals News Today Amphastar Pharmaceuticals News Today Janux Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXAI) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
